Linked Life Data

10828647

Source:http://linkedlifedata.com/resource/pubmed/id/10828647

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2000-7-25
pubmed:abstractText
Glatiramer acetate (copolymer 1) was licensed in the USA in 1996 for the treatment of relapsing-remitting multiple sclerosis. In order to assess its efficacy, a meta-analysis of all randomized controlled trials was performed. Two double-blind studies, accounting for a total number of 299 patients, contribute to this analysis. Patients undergoing the treatment have decreased probability of relapse at 12 months (OR 0.17, 95% CI 0.05-0.51, p = 0.002) and of unsustained progression of disability at 24 and 35 months (OR 0.57, 95% CI 0. 34-0.95, p = 0.031, and OR 0.50, 95% CI 0.28-0.90, p = 0.019). These data suggest that glatiramer acetate represents an alternative to interferon treatment in relapsing-remitting multiple sclerosis. However, further evidence of efficacy is required to justify its use in clinical practice.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0014-3022
pubmed:author
pubmed:copyrightInfo
Copyright 2000 S. Karger AG, Basel.
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
189-93
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Meta-analysis of clinical trials with copolymer 1 in multiple sclerosis.
pubmed:affiliation
Department of Neurology, National Institute of Neurology C. Besta, Institute of Pharmacological Research M. Negri, Milan, Italy. msgroup@istituto-besta.it
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Meta-Analysis